Piotr Serwatowski

7.4k total citations · 4 hit papers
28 papers, 5.3k citations indexed

About

Piotr Serwatowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Piotr Serwatowski has authored 28 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Piotr Serwatowski's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Piotr Serwatowski is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Piotr Serwatowski collaborates with scholars based in Germany, United States and Poland. Piotr Serwatowski's co-authors include U. Gatzemeier, Joachim von Pawel, Johan Vansteenkiste, Raju Titus Chacko, Martin Reck, Igor Bondarenko, Thomas J. Lynch, Fabrice Barlési, Christian Manegold and Giorgio V. Scagliotti and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Piotr Serwatowski

28 papers receiving 5.2k citations

Hit Papers

Phase III Study Comparing Cisplatin Plus Gemcitabine With... 2007 2026 2013 2019 2008 2012 2007 2012 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
  2. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    2012 816 citations Thomas J. Lynch, Igor Bondarenko et al. Journal of Clinical Oncology profile →
  3. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
    2007 706 citations U. Gatzemeier, A Płużańska et al. Journal of Clinical Oncology profile →
  4. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    2012 500 citations Martin Reck, Igor Bondarenko et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Piotr Serwatowski Germany 15 4.0k 3.5k 1.0k 760 626 28 5.3k
Shunichi Sugawara Japan 36 4.2k 1.1× 3.5k 1.0× 1.1k 1.0× 448 0.6× 548 0.9× 209 5.4k
Aleksandra Szczęsna Poland 23 4.4k 1.1× 4.2k 1.2× 1.2k 1.1× 381 0.5× 665 1.1× 73 5.8k
Francesco Orlandi United States 17 4.9k 1.2× 3.2k 0.9× 806 0.8× 853 1.1× 565 0.9× 39 5.6k
Robert M. Jotte United States 31 5.6k 1.4× 4.0k 1.1× 1.4k 1.4× 1.0k 1.4× 744 1.2× 111 6.9k
Martin Sebastian Germany 27 4.1k 1.0× 3.3k 0.9× 1.7k 1.7× 945 1.2× 930 1.5× 117 5.8k
Bilal Piperdi United States 35 3.9k 1.0× 2.8k 0.8× 821 0.8× 493 0.6× 518 0.8× 119 5.0k
Gene Grant Finley United States 19 3.3k 0.8× 2.2k 0.6× 961 0.9× 690 0.9× 466 0.7× 70 4.4k
Achim Rittmeyer United States 26 4.9k 1.2× 3.5k 1.0× 593 0.6× 1.1k 1.4× 687 1.1× 91 5.7k
Ariel López-Chávez United States 18 2.8k 0.7× 1.9k 0.5× 821 0.8× 575 0.8× 465 0.7× 41 3.7k
Neal Ready United States 36 4.2k 1.1× 2.8k 0.8× 1.1k 1.0× 741 1.0× 481 0.8× 160 5.7k

Countries citing papers authored by Piotr Serwatowski

Since Specialization
Citations

This map shows the geographic impact of Piotr Serwatowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piotr Serwatowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piotr Serwatowski more than expected).

Fields of papers citing papers by Piotr Serwatowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piotr Serwatowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piotr Serwatowski. The network helps show where Piotr Serwatowski may publish in the future.

Co-authorship network of co-authors of Piotr Serwatowski

This figure shows the co-authorship network connecting the top 25 collaborators of Piotr Serwatowski. A scholar is included among the top collaborators of Piotr Serwatowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piotr Serwatowski. Piotr Serwatowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2023). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(14). 2458–2466. 17 indexed citations
2.
Meyer, Tim, Evgeny Ledin, Dong‐Wan Kim, et al.. (2022). Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 40(4_suppl). 434–434. 2 indexed citations
3.
Thongprasert, Sumitra, Sarayut Lucien Geater, Dragana Jovanović, et al.. (2019). Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: a Phase IV Study. PubMed. 8(3). LMT15–LMT15. 3 indexed citations
4.
Serwatowski, Piotr, Aleksandra Szczęsna, Joachim von Pawel, et al.. (2017). P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study. Journal of Thoracic Oncology. 12(1). S1214–S1215. 9 indexed citations
5.
Gladkov, Oleg, Rodryg Ramlau, Piotr Serwatowski, et al.. (2015). Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Anti-Cancer Drugs. 26(10). 1061–1068. 18 indexed citations
6.
7.
8.
9.
O’Brien, Mary, Wilfried Eberhardt, Nasser K. Altorki, et al.. (2014). Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.. Journal of Clinical Oncology. 32(15_suppl). 7535–7535. 2 indexed citations
10.
Reck, Martin, Igor Bondarenko, Alexander Luft, et al.. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology. 24(1). 75–83. 500 indexed citations breakdown →
11.
Lynch, Thomas J., Igor Bondarenko, Alexander Luft, et al.. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. Journal of Clinical Oncology. 30(17). 2046–2054. 816 indexed citations breakdown →
12.
Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations
13.
Jaworowska, Ewa, Joanna Trubicka, Marcin Lener, et al.. (2011). Smoking Related Cancers and Loci at Chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish Population. PLoS ONE. 6(9). e25057–e25057. 32 indexed citations
14.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →
15.
Cybulski, Cezary, Dorota Oszutowska–Mazurek, Ewa Jaworowska, et al.. (2008). Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis. 29(4). 762–765. 35 indexed citations
16.
17.
Gatzemeier, U., A Płużańska, Aleksandra Szczęsna, et al.. (2007). Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology. 25(12). 1545–1552. 706 indexed citations breakdown →
18.
Lener, Marcin, Dorota Oszutowska–Mazurek, Grzegorz Kurzawski, et al.. (2005). Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Research and Treatment. 95(2). 141–145. 27 indexed citations
19.
Digumarti, Raghunadharao, P. Koralewski, Piotr Serwatowski, et al.. (2005). P-560 A randomized phase II study of plvanex and docetaxel comparedto docetaxell monotherapy In patients with previously treated advanced NSCLC. Lung Cancer. 49. S265–S265. 3 indexed citations
20.
Serwatowski, Piotr, et al.. (1995). [Analysis of course and treatment results after treatment of pulmonary tuberculosis with early introduction of interrupted observation--preliminary report].. PubMed. 63(5-6). 293–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Francesco Orlandi Breakdown of academic impact, for papers by Robert M. Jotte Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Bilal Piperdi Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Ariel López-Chávez Breakdown of academic impact, for papers by Neal Ready
Rankless by CCL
2026